Background Despite overexpression of the ErbB (EGFR/HER2/ErbB3/ErbB4) family in
castration-resistant prostate cancer (CRPC), some inhibitors of this family, including the dual …

Incurable castration-resistant prostate cancer (CRPC) is driven by androgen receptor (AR)
activation. Potent therapies that prevent AR signaling, such as Enzalutamide (ENZ), are …

Purpose: ErbB2 signaling appears to be increased and may enhance androgen receptor
(AR) activity in a subset of patients with castration-resistant prostate cancer (CRPC), but …

Abstract BACKGROUND AND PURPOSE Although preclinical results suggest that the
inhibition of erb‐B1 or erb‐B2 can be an useful tool to castration resistant prostate cancer …

16037 Background: Epidermal growth factor receptor (EGFR) and human epidermal growth
factor receptor 2 (HER2) tyrosine kinases represent potential targets in prostate cancer …

OBJECTIVES:: Epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases may
be involved in activation of androgen receptor and progression of prostate cancer. They …

The aberrant activation of HER2 has a pivotal role in bone metastasis implantation and
progression in several tumor types, including prostate cancer (PC). Trastuzumab and other …

Objectives: Lapatinib (GW572016) is a selective and potent dual tyrosine kinase inhibitor of
the epidermal growth factor 1 (EGFR) and 2 (HER2), approved in the treatment of HER2 …

Purpose: Despite successful clinical management of castration-sensitive prostate cancer
(CSPC), the 5-year survival rate for men with castration-resistant prostate cancer is only …

Purpose: Patients with recurrent prostate cancer are commonly treated with androgen
withdrawal therapy (AWT); however, almost all patients eventually progress to castration …